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A B S T R A C T
Enhanced expression and activity of protein kinases are critical in tumor cell proliferation and cancer progression.
These various cancer-related kinases form intricate interdependent signaling networks. Evaluation of the effect of
various kinase inhibitors on these networks is critical to understand kinase inhibitor efficacy in cancer therapy. The
dynamic activation of some kinases can be monitored by fluorescence resonance energy transfer (FRET) biosensors
with high temporal resolution. Here, we established a FRET biosensor-based high throughput imaging approach to
determine ERK and AKT activity in two triple negative breast cancer (TNBC) cell lines HCC1806 and Hs578T. FRET
functionality was systematically evaluated using EGF stimulation and different MEK and AKT inhibitors, respectively.
Next, we assessed the effect of a kinase inhibitor library containing>350 different kinase inhibitors (KIs) on ERK and
AKT kinase activity using a FRET high-throughput screening setting. Suppression of FRET-ERK activity was generally
positively correlated with the proliferation phenotype against inhibitors targeting MAPK signaling in both cell lines
containing FRET-ERK reporter. AKT inhibitor (AKTi) resistant HCC1806 showed decreased proliferation associated
with downregulated dynamics of FRET-ERK when treated with KIs targeting protein receptor tyrosine kinase (RTK).
Yet, MEK inhibitor (MEKi) resistant Hs578T showed positively correlated FRET-AKT and proliferative responses against
different PI3K and AKT inhibitors. Altogether, our data demonstrate the feasibility to integrate high throughput
imaging-based screening of intracellular kinase activity using FRET-based biosensors in assessing kinase specificity and
possible signaling crosstalk in direct relation to therapeutic outcome.
1. Introduction
Protein kinases constitute the complexity in signaling networks that
orchestrate extracellular and intracellular signals to control cell growth,
proliferation and survival [1–4]. Deregulation of kinase signaling cascades
underlies the cause of cancer. Triple negative breast cancer (TNBC) is an
aggressive subtype of breast cancer with unfavorable prognosis [5,6]. Ad-
vanced large-scale gene expression profiling has revealed several frequently
altered signaling pathways in TNBC, including high expression of genes in
epithelial-mesenchymal transition and growth factor pathways, enriched
immune cell processes and androgen signaling, and increased cell cycle and
DNA damage responses [7–9]. Particularly, overexpression of receptor tyr-
osine kinases (RTKs) and frequently elevated activation of MAPK/ERK and
PI3K/AKT pathways, the two canonical pathways converging RTK sig-
naling, have been observed in a set of TNBCs [10,11]. Therefore, kinase
targeted therapies with diverse RTK inhibitors, MEK inhibitors (MEKi) and
AKT inhibitors (AKTi) to block upregulated RTK, MAPK/ERK and PI3K/
AKT signaling in TNBC have been explored under clinical investigation
[12–14]. However, TNBC patients do not respond equally well to kinase
targeted therapies, often encountering the problem of inhibitor resistance,
due to upregulated adaptive signaling pathways or drug induced kinome
reprogramming [15–19]. Hence, dissection of kinase dependency is essen-
tial for discovering effective kinase targeted therapeutics for the dismal
TNBC.
Fluorescence resonance energy transfer (FRET) imaging has been ex-
plored in innovating the discovery of effective therapeutics for cancer
therapy [20–23]. In particular, genetically encoded FRET biosensors that
stably express two fluorescent proteins, mostly CFP and YFP (cyan and
yellow fluorescent proteins), enable quantitative measurement of kinase
dynamic activity and real-time monitoring of inhibitor-target potency in
living cells [24]. FRET biosensors are developed based on phosphorylated
peptide substrate of a kinase for its kinase activity [25] or based on
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conformational changes of the kinase itself for its activation [26]. Substrate-
based FRET biosensors have been extensively applied to evaluate the ac-
tivities of kinase targets in response to kinase inhibitors. For example, a
stably expressed FRET biosensor for epidermal growth factor receptor
(EGFR) signaling in HeLa cells was reported to predict the efficiency of
inhibitors targeting Ras-ERK and PI3K-S6K pathways [21]. A designed
FRET kinase translocation reporter was described to dynamically measure
multiple JNK, p38 and ERK activities in live single cells under inhibitor
treatment [27]. A panel of optimized FRET biosensors have been estab-
lished to monitor the kinase activities of PKA, ERK, JNK, EGFR/Abl, Rac1,
RSK, S6K, AKT and PKC in response to EGF stimulation and kinase in-
hibitors [28,29]. Therefore, utilization of substrate-based FRET biosensor
imaging may allow dissecting the complexity of kinase networks in drug-
resistant TNBC cells and predicting effective kinase inhibitors for treating
the refractory TNBC.
We have previously profiled the proliferative responses of 20 TNBC cell
lines to 378 kinase inhibitors (Selleckchem®). Consistent to the clinical re-
sults, our results also demonstrated the differential response phenotype of
TNBC cells to MEK and AKT targeted inhibitors, and defined the groups of
MEKi-resistant and AKTi-resistant TNBC cell lines (van der Noord et al,
Scientific Reports, 2019, in press). In this study, we described a FRET-ERK
and FRET-AKT biosensor based high-throughput imaging approach to
quantitatively monitor ERK and AKT dynamic activity in MEKi-resistant and
AKTi-resistant TNBC cells in response to the 378 kinase inhibitors. We de-
rived a mathematical model that associates MEK and AKT kinase activity
with anti-proliferation effects, by which we revealed unique kinase de-
pendencies on RTK/MAPK and PI3K/AKT pathways that are distinctly
targetable in the resistant TNBC cells.
2. Materials and methods
2.1. Reagents and antibodies
A library of 378-kinase inhibitors (the L1200 library), BEZ235,
AZD5363, erlotinib, gefitinib, selumetinib, GSK1059615, GSK690693
and TAK733 inhibitors were purchased from Selleckchem (Huissen, the
Netherlands). The phospho(Ser473)-AKT (9271), phospho(Thr202/
Tyr204)-p44/42 MAPK (ERK1/2, 9101), GFP (D5.1, 2956), AKT (9272)
and p44/42 MAPK (ERK1/2, 4695) antibodies were from Cell Signaling
(Bioké, Leiden, the Netherlands). The antibody against tubulin (T-
9026), blasticidin S (15205) and human epidermal growth factor (EGF,
E9644) were from Sigma Aldrich (Zwijndrecht, the Netherlands).
2.2. Cell culture
Human TNBC cell line HCC1806 and Hs578T were provided by
Erasmus Medical Center (Rotterdam, the Netherlands). Cells were cul-
tured in RPMI-1640 medium supplemented with 10% fetal bovine
serum, 25 U/mL penicillin and 25 µg/mL streptomycin in a humidified
incubator at 37 °C with 5% CO2.
2.3. Establishment of stable FRET reporter cell line
Constructs of FRET biosensors for ERK (named pPBbsr-EKAREV-nls)
and AKT (named pPBbsr-Eevee-iAKT-nes) have been described pre-
viously [28,29] and kindly provided by Prof. Dr. Michiyuki Matsuda
(Laboratory of Bioimaging and Cell Signaling, Kyoto University, Japan).
Stable cell lines expressing ERK-FRET and AKT-FRET biosensors using a
transposon system were established, as described previously [22].
pCMV-mPBase (mammalian codon-optimized PBase) encoding a pig-
gyBac transposase was a gift from Allan Bradley (Welcome Trust Sanger
Institute, Cambridge, UK). HCC1806 and Hs578T cells were transfected
with pCMV-mPBase and either pPBbsr-EKAREV-nls or pPBbsr-Eevee-
iAKT-nes, and selected with blasticidin S at a dose of 2 μg/ml for
10 days to generate cells expressing EKAREV-nls or Eevee-iAKT. Plas-
mids were transfected using lipofectamine™ 3000 transfection reagent
(Thermo Fisher Scientific, Waltham, USA) according to the manu-
facturer’s instructions. Selected cells were suspended and further FACS
(fluorescence activated cell sorting)-sorted at the Leiden University
Medical Center flow cytometry core facility (Leiden, the Netherlands).
2.4. Cell proliferation assay
A sulforhodamine B (SRB) colorimetric assay was used to measure total
amount of proteins indicative of cell proliferation [30]. Briefly, 4-day post-
treatment, cells in 96-well plates were fixed with 30 µL 50% trichloroacetic
acid for 1 h at 4 °C, followed by gently washing with tap water. Fixed and
air-dried cells were stained with 60 μL of 0.4% SRB (dissolved in 1% acetic
acid) at room temperature for 2 h. Unbound SRBwas washed away with 1%
acetic acid. The protein-bound SRB was solubilized in 10mM unbuffered
Tris base solution at room temperature for 2 h on a plate shaker and
measured for its absorbance at 540 nm with an Infinite M1000 microplate
reader (Tecan, Giessen, the Netherlands).
2.5. FRET KI library screen
Cells were seeded in 96-well plates at appropriate densities in
complete medium and screened in duplicate against the 378-KI library
(Selleckchem®) at 1 μM. Three basal images were captured prior to KI
treatment. FRET imaging was automated continuously for 90min in the
presence of KIs, and proliferation assay was performed 4 days after
treatment. All primary screening data results can be obtained from the
corresponding author upon request.
2.6. siRNA transfection
To silence target genes, 50 nM siGENOME Human SMARTpool
siRNA mix (GE Dharmacon, Lafayette, CO, USA) was transfected into
cells by transfection reagent INTERFERin (Polyplus-Transfection SA,
Illkirch-Graffenstaden, France) according to the manufacturer’s in-
structions. The medium was refreshed 24 h post-transfection and
transfected cells were used in experiments 48 h post-transfection.
2.7. Western blotting
Cells were seeded in 6-well plates at the appropriate density. For
stimulation/starvation assays, medium was refreshed with serum-free
medium (SFM) the following day and cells were starved overnight.
Thereafter, cells were stimulated with 50 ng/ml EGF (Sigma; E9644) for
5min in SFM. Cells were lysed with RIPA buffer containing 1% pro-
tease/phosphatase inhibitor cocktail (Sigma-Aldrich, P8340). Proteins
were resolved by SDS-PAGE and transferred to polyvinylidine di-
fluoride membranes. Membranes were blocked in 5% BSA in Tris-buf-
fered saline with 0.05% Tween-20 (TBS-T), followed by overnight in-
cubation with primary antibodies, washing, and 1 h incubation with
HRP-conjugated secondary antibodies. Chemiluminescence was gener-
ated in the presence of HRP substrate and detected with an Amersham
Imager 600 (GE Healthcare Life Sciences, Eindhoven, the Netherlands).
Protein bands were quantified using ImageJ (NIH, US).
2.8. Time-Lapse imaging
Cells were imaged using a Nikon Eclipse Ti confocal microscope (Nikon,
Amsterdam, The Netherlands) equipped with a PlanApoVC 20x/0.75 ob-
jective lens, a cooled CCD camera, a CoolLED pE-100 excitation light
source, an automated stage and perfect focus system, and an incubation
chamber. The dichroic mirrors and filters used for time-lapse imaging were
as follows: a T640LPXR dichroic mirror, and emission filters FF01-482/35
and FF01-525/50 for CFP and FRET, respectively. All images were acquired
using NIS software (Nikon). 408 nm LED lamp was used as light source,
with 1.4% of lamp power. Acquisition times were 2 s for donor channel and
2 s for FRET at binning 2×2. Cells were plated in 96-well, collagen-coated,
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glass-bottom plate (Greiner, Kremsmünster, Austria). After attachment, cells
were imaged in phenol red-free RPMI-1640 medium at 37 °C. For EGF ex-
posure study, cells were starved at least 12 h and treated with stimulus,
followed by the addition of inhibitors if necessary. 3–5 frames were taken
prior to any compound addition to obtain basal CFP and FRET intensity
level.
2.9. FRET ratio image analysis
Image analysis was implemented using a combination of ilastik (v1.1.9)
and CellProfiler (v2.1.1). Acquired images were split into the original
channels. Segmentation was performed based on FRET images using ilastik.
Mono-channel images were masked with segmentations using CellProfiler.
Fig. 1. Establishment of FRET reporter TNBC cell lines. (A) Percentage of FRET biosensor positive cells sorted by FACS. TNBC cells were transfected with DNA
plasmids encoding FRET-ERK and -AKT biosensors and selected with blasticidin (20 µg/ml) for one week, followed by trypsinization and suspension prior to FACS.
Cells from polyclones were used for FACS sorting. The percentage in each plot indicated the sorting efficiency. (B) Biosensor expression in FRET reporter cells.
Antibody against GFP was used to detect fluorescence of expressed biosensors. Quantification of ERK, AKT and total fluorescent protein level in parental and FRET
reporter TNBC cell lines. The expression level relative to Tubulin was normalized to that in each corresponding FRET-AKT cell line. (C) Fluorescence imaging of FRET
reporter cells. Cells were imaged in GFP channel using ZOE™ fluorescent cell imager. Scale bar= 100 µm. (D) Effects of selumetinib and AZD5363 on cell pro-
liferation of parental and FRET biosensors cell lines. Both parental and FRET-ERK (AKT) reporter HCC1806 and Hs578T cells were treated with selumetinib and
AZD5363 in concentration range for 4 days, followed by SRB proliferation assay. The results were expressed as mean ± SEM of three independent experiments (two-
way ANOVA * p < 0.05, ** p < 0.01, *** p < 0.001).
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The FRET and CFP intensities were quantified per pixel and the FRET was
divided by the CFP channel. In general, for all reporter cell lines and studies,
for each frame,>100 cells were captured for the intensity measurement.
FRET/CFP ratio images were created to represent the FRET efficiency. In
the intensity-modulated display mode, eight colors from red to blue are
used to represent the FRET/CFP ratio. The FRET/CFP value prior to com-
pounds exposure was averaged and used as the reference. The ratio of raw
FRET/CFP value versus the reference value was defined as the normalized
FRET/CFP value. FRET dynamics curve for each treatment was modeled
using R (v3.2.2) and RStudio (v0.99.887) with an in-house developed
“celloscillate” pipeline (Wink et al, manuscript in preparation). Extremes
representing maximum FRET effect were extracted from fitted curves and
defined as MaxMagnitudeFRET.
2.10. Statistical analysis
Pearson correlation analysis were performed using GraphPad Prism 7
with 95% confidence band. Significance was set at r > 0.5. All experi-
ments were performed in at least three independent biological replicates.
Data were expressed as mean ± SEM (standard error of mean). Statistical
analysis was performed using two-way ANOVA (* p < 0.05, ** p < 0.01,
*** p < 0.001) where necessary. The hierarchical clustering in heatmap
was performed using CRAN pheatmap package in RStudio (v0.99.887).
3. Results
3.1. Establishment of stably expressed FRET-ERK and FRET-AKT biosensor
in TNBC cells resistant to MEK or AKT inhibition
To monitor ERK and AKT dynamic activity in control of TNBC cell
proliferation, we firstly ectopically expressed YPet/ECFP pair and substrate-
based FRET-ERK biosensor (EKAREV) and FRET-AKT biosensor (Eevee-
iAkt) [28,29] into an AKTi-resistant TNBC cell line (HCC1806) and a MEKi-
resistant TNBC cell line (Hs578T), respectively. Two stable FRET-ERK bio-
sensor lines (HCC1806/ERK, Hs578/ERK) and two FRET-AKT biosensor
lines (HCC1806/AKT, Hs578T/AKT) were established, overall
achieving>85% of fluorescent positive cell population (Fig. 1A) and high
levels of FRET pair expression (GFP bands) (Fig. 1B, left panel). Ectopic
expression of FRET-ERK and FRET-AKT biosensors did not affect the en-
dogenous ERK and AKT levels, compared to parental cells (Fig. 1B).
Moreover, the homogeneity of the fluorescent protein expression in the
established FRET biosensors cells was visualized via GFP channel of fluor-
escent microscopy (Fig. 1C). In response to proliferative inhibition by MEKi
selumetinib and AKTi AZD5363, HCC1806 FRET biosensor cells remained
MEKi-sensitive and AKTi-resistant, while Hs578T FRET biosensor cells were
AKTi-sensitive and MEKi-resistant, phenocopying the drug responses of
parental cells (Fig. 1D).
3.2. FRET-ERK and FRET-AKT activity in the biosensor TNBC cells are
responsive to EGF stimulation and MEK or AKT inhibition
Since ERK and AKT are essential effectors of EGF-triggered signaling
cascades, we next evaluated FRET-ERK and FRET-AKT activity dy-
namics in the presence of EGF at 10, 25, 50 and 100 ng/ml con-
centrations, respectively. The ratio of fluorescence intensity of the YFP
(acceptor) channel (FRET) versus fluorescence intensity of CFP (donor)
channel (CFP), FRET/CFP, was used to represent the level of FRET-ERK
and FRET-AKT kinase activities [15]. In Hs578T/ERK reporter cells,
FRET-ERK activity was effectively induced by EGF even at low con-
centration of 10 ng/ml, peaking at 10min post-exposure and declining
gradually till 90min (Fig. 2A; Supplementary videos 1 and 2). The rapid
induction of FRET-ERK activity by EGF was also captured in HCC1806/
ERK cells (Fig. 2B; Supplementary videos 3 and 4), but attenuated
swiftly, compared to Hs578T/ERK cells. FRET-AKT activity in Hs578T/
AKT reporter cells was immediately triggered upon EGF stimulation,
being enhanced during the 90-min imaging period (Fig. 2C). The FRET-
ERK and FRET-AKT activities did not show significant EGF dose de-
pendency. The FRET/CFP detection window in our established FRET-
ERK and FRET-AKT biosensor TNBC cells were consistent with that
shown in the original publications [28,29]. It has been reported that
FRET-ERK and AKT signal positively correlates with ERK and AKT
phosphorylation [29,31–33]. Consistently, our western blot results
confirmed the activation of p-ERK in Hs578T/ERK and HCC1806/ERK,
and p-AKT in Hs578T/AKT biosensor cells, when stimulated with EGF
in time course (5, 10, 30, 60 and 120min, at 50 ng/ml) and in con-
centration range (10, 25, 50 and 100 ng/ml, for 5min) (Fig. 2E–G, I–K).
However, HCC1806/AKT cells did not show increased FRET-AKT ac-
tivity in response to EGF exposure (Fig. 2D), although AKT phosphor-
ylation was rapidly induced (Fig. 2H–L). Noteworthy, instant mem-
brane ruffling in HCC1806/AKT cells (Supplementary videos 5 and 6),
but not Hs578T cells (Supplementary videos 7 and 8), was observed
upon the addition of EGF. As the FRET-AKT biosensors were expressed
in cytoplasm, cellular shrinkage might affect the membrane growth
factor receptor-mediated signal transduction and eventually the ratio-
metric FRET measurement [34–36].
Supplementary video 1. Basal FRET-ERK activity dynamics in serum-starved
Hs578T/ERK cells.
Supplementary video 2. EGF (50 ng/ml) stimulated FRET-ERK activity dy-
namics in serum-starved Hs578T/ERK cells.
Supplementary video 3. Basal FRET-ERK activity dynamics in serum-starved
HCC1806/ERK cells.
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Supplementary video 4. EGF (50 ng/ml) stimulated FRET-ERK activity dy-
namics in serum-starved HCC1806/ERK cells.
Supplementary video 5. Basal FRET-AKT activity dynamics in serum-starved
HCC1806/AKT cells.
Supplementary video 6. EGF (50 ng/ml) stimulated FRET-AKT activity dy-
namics in serum-starved HCC1806/AKT cells.
Supplementary video 7. Basal FRET-AKT activity dynamics in serum-starved
Hs578T/AKT cells.
Supplementary video 8. EGF (50 ng/ml) stimulated FRET-AKT activity dy-
namics in serum-starved Hs578T/AKT cells.
Next, we demonstrated that the EGF-stimulated FRET-ERK activity
in Hs578T/ERK cells was dropped down upon 20min exposure to MEKi
selumetinib in dose dependent manner (Fig. 3A), and the ratiometric
FRET intensity was declined post 20min of selumetinib exposure, as
captured by time lapse imaging (Fig. 3B; Supplementary video 9). Si-
milarly, the EGF-stimulated FRET-AKT activity in Hs578T/AKT cells
was subject to the inhibitory effect of AKTi AZD5363 (Fig. 3C, D;
Supplementary video 10).
Supplementary video 9. Effects of MEKi selumetinib (1 µM) on FRET-ERK
activity dynamics in the presence of EGF (50 ng/ml) in Hs578T/ERK cells.
Supplementary video 10. Effects of AKTi AZD5363 (1 µM) on FRET-AKT ac-
tivity dynamics in the presence of EGF (50 ng/ml) in Hs578T/AKT cells.
To clarify if the EGF-induced FRET kinase activity is attributed to
EGFR signaling transduction upon EGF stimulation, we silenced EGFR
and ERK2 in Hs578T/ERK cells by siRNA transfection, with AKT1 si-
lencing as negative control. Knockdown of EGFR or ERK2, not AKT1,
markedly blocked EGF-induced FRET-ERK activity in Hs578T/ERK cells
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(Fig. 4A) and moderately in HCC1806/ERK cells (Fig. 4B). The limited
FRET-ERK blockade by silencing EGFR and ERK2 in HCC1806/ERK
suggests that, besides EGFR and ERK2, other signaling components may
contribute to the FRET-ERK activity in the AKTi-resistant cells.
Taking together, our established FRET-ERK and FRET-AKT bio-
sensor TNBC cell models are applicable for capturing ERK and AKT
dynamic activities in response to EGF/EGFR signaling cascades and
inhibition of MAPK/ERK and PI3K/AKT upstream signaling pathways.
3.3. FRET-ERK and FRET-AKT imaging-based kinase inhibitor screening
reveals multiple signaling pathways interacting with ERK and AKT kinase
activity for TNBC cell proliferation
MAPK/ERK and PI3K/AKT pathways are the major intracellular
mechanisms in response to extracellular signaling cues to control cell
survival, proliferation, cell cycle and DNA damage [37–41]. To char-
acterize ERK and AKT dynamic kinase activities in relation to kinase
inhibition and proliferation in TNBC cells, we performed high-
throughput FRET screening and proliferation screening with 378 in-
hibitors (Selleckchem®) targeting 118 kinases in the FRET-ERK and
FRET-AKT biosensor TNBC cells above. FRET imaging was automated
continuously for 90min in the presence of kinase inhibitors (1 µM), and
proliferation assay was performed 4 days after treatment. To evaluate
FRET kinase activities in response to individual inhibitors, we modeled
each temporal FRET dynamics curve based on FRET/CFP ratio and
extracted fitted value for maximum FRET effect (MaxMagnitudeFRET).
Pearson correlation analysis of the fitted value for each replicate
showed high reproducibility of the FRET screening in each FRET bio-
sensor cell line (r > 0.8, Fig. 5A–D). Pearson coefficient r for pro-
liferation assays demonstrated high reproducibility of the replicate
Fig. 2. FRET-ERK and FRET-AKT activity dynamics in response to EGF exposure. (A–D) Dynamics of FRET-ERK (A, B) and FRET-AKT (C, D) activity upon concentration range
of EGF exposure. FRET reporter cells were serum-starved overnight and exposed to EGF at different concentrations. Five basal images were taken before EGF (ng/ml) was
added. (E–H) Effects of EGF exposure on ERK (E, F) and AKT (G-H) phosphorylation. FRET reporter cells were serum-starved overnight and exposed to EGF in time course (left
panel, 50 ng/ml) and concentration range (right panel, 5min). (I–L) Quantification of phosphorylated ERK (I, J) and AKT (K, L) level, derived from (E–H). The expression level
relative to total ERK or AKT was normalized to that in the sample exposed to EGF (50 ng/ml) for 5min, the second bar. The results were expressed as mean ± SEM of three
independent experiments.
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proliferation screens (r > 0.9, Fig. 5E–H). The maximum FRET effect
was plotted to relative proliferation for each kinase inhibitor for each
FRET biosensor cell line. Given that the positive control for FRET-ERK
(i.e. selumetinib) and FRET-AKT (i.e. AZD5363) achieved 0.8 and 0.96,
respectively, we considered half maximum inhibitory effect on pro-
liferation (50%) and FRET/CFP ratio 0.9 for FRET-ERK activity and
0.98 for FRET-AKT activity as effective inhibition. Consequently, 44
kinase inhibitors were screened to effectively inhibit both FRET-ERK
activity and proliferation in HCC1806/ERK cells, while only 8 in
Hs578T/ERK cells (Fig. 5I, J). In HCC1806/AKT and Hs578T/AKT
biosensor cells, 14 and 26 inhibitors were selected, respectively
(Fig. 5K, L). The FRET-ERK biosensor inhibitors mainly target signaling
components in RTK and MAPK pathways, and the FRET-AKT effective
inhibitors mostly suppress the kinases of PI3K/AKT pathway (Fig. 5M).
The FRET-ERK and FRET-AKT biosensor inhibitors also block the sig-
naling networks of angiogenesis, cell cycle, epigenetics, NF-κB, cytos-
keletal signaling, JAK/STAT and DNA damage, indicating their inter-
play with MAPK/ERK and PI3K/AKT pathways.
Fig. 3. Effects of MEK and AKT inhibitors on FRET-ERK and FRET-AKT activity. (A-D) Effects of selumetinib (Sel) and AZD5363 (AZD) on FRET-ERK (A-B) and FRET-
AKT (C-D) activity dynamics in the presence of EGF. FRET reporter cells were serum-starved overnight and exposed to EGF at 50 ng/ml. Five basal images were taken
before EGF was added. Arrow indicates when EGF, Sel or AZD was added; values represent µM. Raw FRET/CFP ratio was color-coded in rainbow scale. Scale
bar= 100 µm. The results were expressed as mean ± SEM of three independent experiments.
Fig. 4. EGFR and ERK played a role in EGF-stimulated FRET-ERK. (A, B) Effects of EGFR, ERK2 or AKT1 siRNA knockdown on EGF-stimulated FRET-ERK in Hs578T/
ERK (A) and HCC1806/ERK (B) cells. FRET reporter cells were transfected with siRNAs for 48 h and serum-starved overnight prior to exposure to EGF at 50 ng/ml.
Five basal images were taken before EGF was added. The results were expressed as mean ± SEM of three independent experiments.
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3.4. FRET-ERK and FRET-AKT imaging for ERK and AKT activity
visualizes RTK/MAPK and PI3K/AKT dependencies for TNBC cell
proliferation
The observation above that RTK, MAPK and PI3K/AKT pathways
were most frequently targeted by FRET-ERK and FRET-AKT biosensor
inhibitors, suggests their essential role in TNBC cell proliferation. Next,
we explored the relationship between the FRET effect
(MaxMagnitudeFRET) and proliferation in response to inhibitors tar-
geting RTK, MAPK and PI3K/AKT pathways. In response to MAPK in-
hibitors (MAPKi), both HCC1806 and Hs578T FRET-ERK biosensor cell
lines displayed strong positive correlation between cell proliferation
Fig. 5. FRET KI screen identifies differential kinase dependencies in TNBC cells. (A–H) Reproducibility of FRET kinase inhibitor (KI) screen on FRET (A–D) and cell
proliferation (E–H). Pearson correlation coefficient r showing reproducibility of replicate screen in FRET reporter cells. Maximum magnitude FRET effect
(MaxMagnitudeFRET) was extracted from fitted time-lapse FRET dynamic curve. Blue dots, MEKi. Green dots, AKTi. (I–L) Association of relative proliferation of each
KI with maximum magnitude effects on FRET in reporter cell lines. KIs showing relative proliferation≤50% and MaxMagnitudeFRET ERK (AKT)≤0.9 (0.98) are
numbered and circled. On the graphs displayed the averaged results of the replicate screen. (M) Donut plot of KIs selected from (I–L). Numbers of KIs and their
targeted signaling pathways are annotated. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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and FRET-ERK activity (r= 0.8318 and r= 0.8557, respectively)
(Fig. 6A). While the proliferation of HCC1806/ERK cells was highly
related to RTK-mediated FRET-ERK activity (r= 0. 7623), Hs578T/ERK
cells were poorly responsive to RTK inhibitors (RTKi) with low corre-
lation (r= 0.3680) in proliferation and FRET-ERK activity (Fig. 6B).
Furthermore, hierarchical analysis of time-resolved FRET dynamics
data clustered the MAPKi effect on FRET-ERK biosensor cells, revealing
some MEK inhibitors correlatively inhibiting FRET-ERK activity and
proliferation in both HCC1806/ERK and Hs578T/ERK cells (Fig. 6C). A
group of RTKi, including EGFR inhibitors (EGFRi), displayed con-
current inhibitory effect on FRET-ERK activity and proliferation in
HCC1806/ERK cells, not in Hs578T/ERK cells (Fig. 6D), indicating the
RTKi resistance in Hs578T cells.
In FRET-AKT biosensor cells, positive correlation in FRET-AKT ac-
tivity and proliferation was monitored in Hs578T/AKT cells when
treated with PI3K inhibitors (PI3Ki, r= 0.7383) or AKT inhibitors
(AKTi, r= 0.5534), whereas HCC1806/AKT cells were less responsive
to PI3K/AKT inhibition (Fig. 7A, B). Consistently, FRET-AKT dynamics
clustering displayed the sensitivity to PI3K/AKT signaling inhibition in
Hs578T/AKT cells, but resistance in HCC1806/AKT cells (Fig. 7C, D).
Altogether, our integrated FRET biosensor and kinase inhibitor
screening dissects the RTK/MAPK-dependent proliferation in HCC1806
TNBC cells that are resistant to PI3K/AKT inhibition, and the PI3K/
AKT-dependent proliferation in Hs578T TNBC cells that are RTKi/
MEKi-resistant.
3.5. MEKi-resistant and AKTi-resistant TNBC cells display differential
FRET-ERK and FRET-AKT dynamics in response to RTK/MAPK and PI3K/
AKT inhibition
To confirm the findings on kinase signaling dependencies in AKTi-
resistant HCC1806 and RTKi/MEKi-resistant Hs578T TNBC cells, we
further investigated the inhibitory effects of RTK/MAPK and PI3K/AKT
inhibitors in escalating doses (0.316, 1 and 3.16 µM) on FRET-ERK and
FRET-AKT dynamics in the FRET-ERK and FRET-AKT biosensor cell
lines. Treatment with MEKi, selumetinib decreased FRET/CFP ratio in
HCC1806/ERK and more significantly in Hs578T/ERK cell lines in a
dose dependent fashion, while TAK733 effectively inhibited FRET-ERK
activity even at low dose (0.316 µM) in both cell lines (Fig. 8A, upper
panels). Distinctively, EGFRi gefitinib and erlotinib dramatically de-
creased FRET-ERK signal in HCC1806/ERK cells, but hardly ever in
Hs578T/ERK cells (Fig. 8A, lower panels), revealing the EGFRi re-
sistance in Hs578T cells. These differential FRET-ERK dynamic changes
in HCC1806/ERK and Hs578T/ERK cells were captured, representa-
tively upon 30min exposure to MEKi selumetinib and TAK733 and
EGFRi geftinib and erlotinib at 1 µM (Fig. 8B).
Fig. 6. Correlation between inhibition of FRET-ERK and cell proliferation by selective kinase inhibitors. (A, B) Association of MaxMagnitudeFRET with relative
proliferation of KIs targeting MAPK signaling (MAPKi, A) and Receptor tyrosine kinase (RTKi, B) in FRET-ERK reporter cells. 95% confidence band is shown in grey.
Significance is set at Pearson correlation coefficient r > 0.5 (red). (C, D) Clustering of FRET-ERK activity dynamics against MAPKi (C) and RTKi (D). Heatmaps were
vertically clustered across KIs, annotated with relative proliferation and corresponding targets. FRET/CFP ratio was normalized to DMSO control. Arrow indicates
when KIs were added. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Next, PI3Ki and AKTi conferred inhibitory effect on FRET-AKT ac-
tivity in both HCC1806/ERK and Hs578T/AKT cell lines, yet, in dif-
ferent patterns. The inhibited FRET-AKT by PI3Ki GSK1059615 and
BEZ235 in HCC1806/ERK cells was gradually recovered within one
hour, whilst the FRET-AKT in Hs578T cells was steadily restrained in
dose dependence (Fig. 8C, left panels). AKTi AZD5363 and GSK690693
suppressed FRET-AKT activity more effectively in Hs578T/AKT cells
than in HCC1806/AKT cells (Fig. 8C, right panels).
As a result, our FRET biosensor-based live imaging deciphered the
ERK dynamic responsiveness to EGFRi in AKTi-resistant HCC1806
TNBC cells and the AKT dynamic responsiveness to PI3Ki and AKTi in
MEKi-resistant Hs578T cells that are also highly refractory to EGFRi.
3.6. EGFRi-refractory TNBC cells sustain ERK signaling for proliferation
In EGFRi-refractory Hs578T TNBC cells, EGFRi failed to inhibit
FRET-ERK activity, while the FRET-AKT activity was targetable by
PI3Ki and AKTi, suggesting that the downstream ERK signaling by-
passes EGFR inhibition, leading to resistance. Thus, we further ad-
dressed how the FRET-ERK dynamic activity is associated with pro-
liferative responses to EGFRi, MEKi, PI3Ki and AKTi, respectively, in
dose ranges. The proliferation assays demonstrated that Hs578T/ERK
cells were highly resistant to EGFRi (gefitinib and erlotinib), main-
taining low sensitivity to MEKi (selumetinib and TAK733) and highly
responding to PI3Ki (BEZ235) and AKTi (AZD5363) (Fig. 9A, left).
Contrastingly, the AKTi-resistant HCC1806/ERK cells were responsive
to EGFRi and MEKi but relatively insensitive to PI3Ki and AKTi
(Fig. 9A, right). Next, we assessed if the FRET-ERK activity dynamics
would reflect the ERK phosphorylation status in Hs578T/ERK and
HCC1806/ERK cells in response to representative inhibitors. Strikingly,
EGFRi gefitinib eliminated ERK phosphorylation (p-ERK) in HCC1806/
ERK cells, but left the downstream p-ERK signaling intact in Hs578T/
ERK cells (Fig. 9B, C). MEKi suppressed ERK phosphorylation in both
cell lines, correlating with downregulated FRET-ERK activity dynamics,
while PI3Ki and AKTi conferred no significant changes on p-ERK status
in the cells, as expected. Taken together, the FRET-ERK dynamic ac-
tivity was indicative of ERK signaling and proliferation of TNBC cells in
response to inhibition of signaling pathways, such as RTK, MAPK and
PI3K/AKT.
4. Discussion
TNBC is an aggressive disease with unfavorable prognosis [5,6]. Cur-
rently, there are no effective targeted therapies approved for the treatment
of TNBC patients. Given the pivotal role of EGFR/MAPK and PI3K/AKT
signaling in controlling cell growth, survival and proliferation, central nodes
of these pathways, MEK and AKT, have been emerging as promising targets
for cancer drug discovery [42,43]. MEK inhibitors and AKT inhibitors have
been explored for the treatment of TNBC in the past decades. However, the
clinical outcomes are unfavorable due to drug-induced activation of alter-
native survival signaling pathways [15,44]. Here we have established and
systematically characterized a panel of FRET-ERK and FRET-AKT TNBC
reporter cell lines. We have applied this FRET reporter panel in high-
throughput screening to uncover contextual kinase signaling dependencies
in TNBC that modulate AKT and ERK pathways. Thus, we identified ten
signaling pathways associated with the proliferative response of TNBC to
kinase drugs.
Different TNBC cell lines demonstrate alternative resistance to AKT
or MEK inhibitors, suggesting dependencies on either ERK or AKT sig-
naling for their enhanced proliferation. In AKTi-resistant cells, targeting
various receptor tyrosine kinases, MAPKs, cell cycle-related kinases,
PI3K/AKT and angiogenesis caused a downregulation of FRET-ERK
Fig. 7. Correlation between inhibition of FRET-AKT and cell proliferation by selective kinase inhibitors. (A, B) Association of MaxMagnitudeFRET with relative
proliferation of KIs targeting PI3K (PI3Ki, A) and AKT (ATKi, B) in FRET-AKT reporter cells. 95% confidence band is shown in grey. Significance is set at Pearson
correlation coefficient r > 0.5 (red). (C, D) Clustering of FRET-AKT activity dynamics against PI3Ki (C) and AKTi (D). Heatmaps were vertically clustered across KIs,
annotated with relative proliferation and corresponding targets. FRET/CFP ratio was normalized to DMSO control. Arrow indicates when KIs were added. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Fig. 8. Potency of selected kinase inhibitors on FRET-ERK and FRET-AKT activity. (A) Concentration response FRET-ERK activity dynamics for selumetinib, TAK733,
gefitinib and erlotinib. (B) Representative images taken from (A) at 1 µM. Raw FRET/CFP ratio was color-coded in rainbow scale. Scale bar= 100 µm. (C)
Concentration response of FRET-AKT activity dynamics for GSK1059615, BEZ235, AZD5363 and GSK690693. Three basal images were taken prior to KI treatment in
dose range (µM). KIs showing positive correlation between MaxMagnitudeFRET and proliferation are marked in red. Arrow indicates when KIs were added. The
results were expressed as mean ± SEM of three independent experiments. (For interpretation of the references to color in this figure legend, the reader is referred to
the web version of this article.)
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dynamics, accompanied by attenuated proliferation. This included in-
hibitors targeting VEGFR (ZM 306,416 and AEE788), ALK (AP26113),
MEK (TAK733), cell cycle (AZD7762 and TAK901), and Src (dasatinib).
MEKi-resistant cells were addicted to PI3K/AKT and cell cycle regulated
FRET-AKT activity. Further, we note that targeting PI3K/AKT and an-
giogenesis pathways did suppress FRET-ERK activity.
The MAPK signaling and PI3K/AKT signaling are two canonical
pathways of RTK signal transduction, functioning in a variety of cellular
processes [1,45]. Transcriptomics and proteomics profiles on TNBC
samples indicate that activation of both pathways is frequently ob-
served, but can be attributed to variable reasons. Ras and Raf are rarely
mutated in TNBC [7,9]. However, activation of upstream RTKs and
inactivation of negative regulators, such as NF1 mutation and DUSP4
loss, lead to active MAPK signaling [15,46–48]. Activation of PI3K
pathway, either directly by PI3KCA mutation or indirectly by PTEN or
INPP4B loss, is common in TNBC tumors [7,9,49]. Our KI screening
data have demonstrated that the effects of MAPK inhibition on TNBC
cell proliferation positively correlate with their efficacy on ERK ac-
tivity. The inhibitory effects of RTKi on cell proliferation and ERK ac-
tivity are better correlated in RTKi/MEKi-resistant cells than AKTi-re-
sistant cells. Inhibition of PI3K/AKT signaling is efficacious to suppress
cell proliferation in RTKi/MEKi-resistant subgroups. Complementary to
accumulating molecule signature studies, our findings on differential
kinase dependencies using our FRET reporter panel, provide experi-
mental evidence for the development and prioritization of precision
medicine for TNBC cohorts.
Kinase drugs have been preferably pursued as promising targeted
therapeutics due to the pivotal role of kinase molecules in signal
transductions and corresponding cell biological processes [14,43,50].
Given the hypothesis that kinases with enhanced expression or acti-
vating mutations hold the essentialities in cancer cell progression, gene
expression signatures have been extensively studied and employed to
identify common genetic background within cancer types [51,52].
However, a number of studies suggest that gene expression is rarely
indicative of kinase activity, perturbation of which is a key factor for
evaluating the effectiveness of kinase drugs [53,54]. In this study, es-
tablishment of high-content FRET-based live cell imaging enables dy-
namic quantitative detection of intracellular activity of ERK and AKT,
two key elements in kinase signaling cascades. Our results illustrate that
the influences on kinase activity incarnate the proliferative response of
TNBC to kinase drugs in a temporal and direct way. We anticipate that
FRET-based signaling reporters will contribute substantially to monitor
the efficacy of candidate kinase inhibitors, but also will contribute to
the further understanding of their mode-of-action in relation to cross-
talk with well-defined signaling components in cancer, including ERK
and AKT signaling.
In summary, our work describes an integrated protein kinase de-
pendency identification and functional validation approach that
identifies TNBC kinase addictions, potential targetable pathways and
associated targeted therapeutics. We demonstrate the feasibility of
FRET imaging-based high-content screening of intracellular kinase ac-
tivity in assessing kinase specificity and possible signaling crosstalk. In
particular, our study reveals the intact ERK kinase signaling which
drives TNBC drug resistance against RTKi/MAPKi-targeted therapies.
Besides RTKi and MAPKi, AKTi-resistant cells are also responsive to cell
cycle inhibition via ERK downregulation. Future studies should aim at
broadening the range of cancer relevant kinase biosensors and trans-
lating this approach to in vitro/in vivo models that are closer to the
clinic, including cultures of patient-derived xenograft.
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